Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06888388 · ClinicalTrials.gov registry record
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
A clinical trial of Breast Cancer Surgery, sponsored by Sir Mortimer B. Davis - Jewish General Hospital.
- Recruiting
- Registry status
- 4,700
- Enrollment target
- 12
- Study locations
NCT06888388 is a study of Breast Cancer Surgery that is actively recruiting participants, run by Sir Mortimer B. Davis - Jewish General Hospital. The registered enrollment target is 4,700 participants. The trial reports 12 study locations across 8 states.
The verdict
NCT06888388, a study of Breast Cancer Surgery, is actively recruiting participants, sponsored by Sir Mortimer B. Davis - Jewish General Hospital.
- RECRUITING
- Registry status
- 4,700 participants
- Enrollment target
- 12
- Study locations
Study Summary
Patients with a germline pathogenic variant (GPV) in high-penetrance breast cancer susceptibility genes who are considering risk reducing mastectomy (RRM) often strongly desire to keep their nipple areola complex but inquire as to whether it is safe to do so. Relative to traditional or skin sparing mastectomy (SSM) techniques, nipple sparing mastectomy (NSM) is associated with improved psychosocial and sexual well-being and is significantly better for body image and reducing feelings of disfigurement. Despite this, guidelines have yet to endorse the use of NSM over other RRM techniques, stating that more data and longer follow-up are needed to confirm it as a safe and effective strategy in GPV carriers. As NSM was not routinely adopted in high-risk patient populations undergoing RRM before 2010, there has been little data to inform the long-term oncologic safety of NSM. Well-designed studies have reported low to negligible rates of subsequent breast cancer in BRCA1/2 carriers following NSM, but have been limited by short median follow-up of less than 3 years. The current study is designed to confirm, with longer follow-up, prior findings on the oncologic safety of NSM in unaffected BRCA1/2 carriers. The investigators will also expand data to other high-penetrance GPV carriers, including PALB2, CDH1, PTEN, and TP53, for whom there is little-to-no data on outcomes following RRM.
Conditions Studied
Interventions
- PROCEDURE Nipple Sparing Mastectomy (NSM)
- PROCEDURE Skin-Sparing Mastectomy (SSM)
- PROCEDURE Total (Simple) Mastectomy
Study Locations (12)
Other
- University of Melbourne, Peter MacCallum Cancer Center - Melbourne
- Ziekenhuis Aan de Stroom - Antwerp
- Champalimaud Foundation, University of Lisbon - Lisbon
Ontario
- Hamilton Health Sciences - Hamilton
- Women's College Hospital, University of Toronto - Toronto
Quebec
- Jewish General Hospital - Montreal
- CHU de Quebec Université laval - Québec
Connecticut
- Yale University - New Haven
Massachusetts
- Brigham and Women's Hospital - Dana-Farber Brigham Cancer Center - Boston
New York
- Memorial Sloan Kettering Cancer Center (MSKCC) - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
Alberta
- University of Calgary - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,700 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2028-02-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06888388
The ClinicalTrials.gov registry entry for NCT06888388 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 4,700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sir Mortimer B. Davis - Jewish General Hospital, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer Surgery appearing as the primary indexed condition, and to 3 interventions - of which Nipple Sparing Mastectomy (NSM) is the first listed.
NCT06888388 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Other, Ontario, Quebec.
Frequently Asked Questions
What is clinical trial NCT06888388 about?
NCT06888388 is a clinical study titled "Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer". Patients with a germline pathogenic variant (GPV) in high-penetrance breast cancer susceptibility genes who are considering risk reducing mastectomy (RRM) often strongly desire to keep their nipple areola complex but inquire as to whether it is safe to do so. Relative to traditional or skin sparing ...
What is the current status of trial NCT06888388?
This trial is currently recruiting. The enrollment target is 4,700 participants. The study started on 2025-02-01. Estimated completion is 2028-02-01.
What conditions does trial NCT06888388 study?
This clinical trial studies the following conditions: Breast Cancer Surgery.
What interventions are being tested in trial NCT06888388?
The interventions under investigation include: Nipple Sparing Mastectomy (NSM) (PROCEDURE), Skin-Sparing Mastectomy (SSM) (PROCEDURE), Total (Simple) Mastectomy (PROCEDURE).
Who is sponsoring clinical trial NCT06888388?
This trial is sponsored by Sir Mortimer B. Davis - Jewish General Hospital, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06888388 being conducted?
This trial has 12 study locations across Connecticut, Massachusetts, New York, Pennsylvania, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.